CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

CVRx (NASDAQ: CVRX) announced that Humana issued a Medicare Advantage coverage policy for its Barostim therapy, effective May 1, 2026.

Rhea-AI Summary

CVRx (NASDAQ: CVRX) announced that Humana issued a Medicare Advantage coverage policy for its Barostim therapy, effective May 1, 2026. Humana covers about 5.2 million Medicare Advantage members across 46 states.

The policy applies to Barostim’s current FDA-approved indication and to patients in the BENEFIT-HF heart failure trial. CVRx calls this the first coverage policy for Barostim. It follows new Category I CPT codes and CMS Category B IDE coverage for BENEFIT-HF patients, both effective January 1, 2026.

Positive

• Humana Medicare Advantage coverage for Barostim effective May 1, 2026
• Access to Humana’s approximately 5.2 million Medicare Advantage members in 46 states
• Coverage includes FDA-approved indication and BENEFIT-HF trial participants
• First formal coverage policy for Barostim, noted by CVRx as a key milestone
• Category I CPT codes for Barostim procedure effective January 1, 2026
• CMS Category B IDE coverage for BENEFIT-HF trial patients from January 1, 2026

Negative

• None.

Argus May 14 session

+9.96% close to close Open Argus

Details

News Market Reaction – CVRX

In the May 14 session, CVRX gained 9.96%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +10.0% in the session following this news. A strong positive reaction aligns with th...

Analysis

The stock moved +10.0% in the session following this news. A strong positive reaction aligns with the strategic importance of Humana’s Medicare Advantage coverage policy, which applies to 5.2 million members across 46 states and supports both FDA-indicated and BENEFIT-HF patients. Historically, CVRx has seen mixed price responses to good news, so investors may watch how reimbursement adoption, utilization trends, and any future use of the $150,000,000 shelf interact with sentiment over time.

Key Figures

Humana MA members: 5.2 million States covered: 46 states Humana coverage effective: May 1, 2026 +2 more

Humana MA members

5.2 million

Medicare Advantage members covered across 46 states

States covered

46 states

Humana Medicare Advantage geographic footprint

Humana coverage effective

May 1, 2026

Start date for Humana Medicare Advantage Barostim coverage policy

Category I CPT effective

Jan. 1, 2026

Category I CPT codes for Barostim procedure took effect

CMS Category B IDE

Jan. 2026

CMS approved Category B IDE coverage for BENEFIT-HF patients

Historical Context

5 past events · Latest: May 11

5 events

1. May 11

   Q1 2026 earnings

   24h Move

   -23.8%

   Reported 20% revenue growth and higher margins but shares fell sharply next day.

2. May 04

   Trial enrollment news

   24h Move

   -3.8%

   Announced first patient enrolled in BENEFIT-HF expansion trial; stock reacted modestly lower.

3. Apr 27

   Earnings date set

   24h Move

   -2.2%

   Scheduled Q1 results and call; shares edged down ahead of the report.

4. Apr 20

   Board nomination

   24h Move

   +5.0%

   Named experienced medtech executive Michael Dale to board; stock rose on announcement.

5. Apr 13

   Prelim Q1 results

   24h Move

   +9.2%

   Pre-announced Q1 revenue growth near 20% and strong margins; shares moved higher.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

medicare advantage, neuromodulation, category i cpt codes, centers for medicare & medicaid services (cms)

4 terms

medicare advantage regulatory

"Humana has issued a Medicare Advantage coverage policy for Barostim therapy"

Medicare Advantage is a type of health insurance plan offered by private companies that covers services traditionally provided by government-run Medicare. Think of it as a bundled package that combines hospital, doctor, and other medical care into one plan, often with added benefits. For investors, it matters because the popularity and profitability of these plans can influence healthcare companies and the broader health insurance industry.

neuromodulation medical

"commercializing innovative neuromodulation solutions for patients with cardiovascular diseases"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

category i cpt codes regulatory

"Effective Jan. 1, 2026, Category I CPT codes went into effect for the Barostim procedure"

Category I CPT codes are standardized numeric labels used by doctors and hospitals to describe common medical procedures and services for billing and insurance purposes. Think of them like a universal price tag and barcode for a medical service: having a Category I code makes it easier for providers to bill insurers and for payers to decide coverage, which directly affects how reliably and quickly a procedure generates revenue and is adopted across the health system.

centers for medicare & medicaid services (cms) regulatory

"the Centers for Medicare & Medicaid Services (CMS) approved Category B IDE coverage"

A federal agency that runs the United States' major public health insurance programs for older adults, people with disabilities, and low-income individuals. Investors watch its rules, reimbursement rates and coverage decisions because they directly affect the revenue and costs of healthcare providers, drug makers and medical device companies—like a referee whose calls change how the game is played and who scores.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Humana has issued a Medicare Advantage coverage policy for Barostim therapy, effective May 1, 2026. Humana, a national health insurance company with the second largest Medicare Advantage program in the U.S., provides coverage to approximately 5.2 million Medicare Advantage members across 46 states.

The new policy covers Barostim for patients meeting its current FDA-approved indication as well as patients enrolled in the BENEFIT-HF trial, the landmark heart failure study evaluating Barostim in a significantly expanded patient population initiated earlier this year.

“We are pleased to receive this Medicare Advantage coverage policy from Humana, which represents the first coverage policy for Barostim and marks an important milestone in our efforts to expand access to the therapy for patients living with heart failure,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “Humana’s policy reflects continued progress in educating payers on the clinical outcomes and patient benefits of Barostim therapy. We believe this policy validates our commercial strategy, supports ongoing discussions with other regional and national payers, and will help accelerate adoption of Barostim through more consistent coverage.”

This coverage policy follows two other positive reimbursement developments for Barostim this year. Effective Jan. 1, 2026, Category I CPT codes went into effect for the Barostim procedure. In addition, that same month, the Centers for Medicare & Medicaid Services (CMS) approved Category B IDE coverage for patients enrolled in the BENEFIT-HF trial.

About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Humana announce about Barostim coverage for CVRx (NASDAQ: CVRX) Medicare Advantage members?

Humana issued a Medicare Advantage coverage policy for Barostim, effective May 1, 2026. According to CVRx, the policy applies across Humana’s national Medicare Advantage program for eligible patients, expanding reimbursement access for this heart failure neuromodulation therapy.

When does Humana’s Medicare Advantage coverage policy for Barostim take effect for CVRX shareholders to note?

Humana’s Medicare Advantage coverage policy for Barostim becomes effective on May 1, 2026. According to CVRx, this timing follows earlier 2026 reimbursement enhancements, including new Category I CPT codes and CMS Category B IDE coverage supporting the BENEFIT-HF clinical trial.

Which patients are covered under Humana’s Barostim Medicare Advantage policy for CVRx (CVRX)?

Humana’s policy covers patients meeting Barostim’s current FDA-approved indication and BENEFIT-HF trial participants. According to CVRx, this includes those in the landmark heart failure study evaluating Barostim in a significantly expanded patient population initiated earlier in 2026.

How many Medicare Advantage members could Barostim potentially reach through Humana’s coverage for CVRX?

Humana provides Medicare Advantage coverage to approximately 5.2 million members across 46 states. According to CVRx, the new Barostim policy applies within this program, creating a broad potential covered population for eligible heart failure patients who meet policy criteria.

Why does CVRx consider Humana’s Barostim coverage policy important for CVRX investors?

CVRx characterizes Humana’s policy as the first coverage policy for Barostim and an important milestone. According to CVRx, it supports payer education, ongoing discussions with other payers, and may help accelerate adoption through more consistent reimbursement coverage.

What recent reimbursement developments support Barostim and the BENEFIT-HF trial for CVRx (NASDAQ: CVRX)?

Two key changes took effect January 1, 2026: Category I CPT codes for the Barostim procedure and CMS Category B IDE coverage for BENEFIT-HF patients. According to CVRx, these measures complement Humana’s Medicare Advantage policy for Barostim.